Primary Analysis Results of the Single-Arm Phase Ii Study of Mor208 Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-Mind)
Hematological Oncology - United Kingdom
doi 10.1002/hon.130_2629
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley